$1.600
+0.235 (+14.70%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Neurosense Therapeutics Ltd (NRSN) Moving Averages Convergence Divergence (MACD) indicator is -0.94, suggesting NRSN is Strong sell.
Neurosense Therapeutics Ltd (NRSN) 20-Day simple moving average is 2.36, while Neurosense Therapeutics Ltd (NRSN) share price is $—, making it Sell.
Neurosense Therapeutics Ltd (NRSN) 60-Day simple moving average is 5.32, while Neurosense Therapeutics Ltd (NRSN) share price is $—, making it Sell.
Technical Analysis for NRSN
AI Technical NRSNAs of 2026-11-07, the technical board for Neurosense Therapeutics Ltd (NRSN) reads strong sell: 2 indicators are flashing buy, 8 are indicating sell, and 3 are neutral. Price at $1.60 sits below the 10-day, 20-day, 60-day and 200-day moving averages and above the 5-day.
Momentum readings: RSI stands at 27.919, MACD stands at -0.936 (Sell), Stochastic %K stands at 22.046, Stochastic %D stands at 15.771 and CCI stands at -104.542 (Buy).
NRSN trades below the 60-day SMA (5.32) and below the 200-day SMA (12.42). Immediate resistance sits at Classic R1 2.69, then R2 3.55. Support sits at Classic S1 1.04, then S2 0.25.
Neurosense Therapeutics Ltd (NRSN) Support & Resistance Level
Neurosense Therapeutics Ltd (NRSN) Technical Indicators
2026-11-07
| Name | Value |
|---|---|
| RSI_14 | 27.919 |
| STOCHk_14_3_3 | 22.046 |
| STOCHd_14_3_3 | 15.771 |
| CCI_20 | -104.542 |
| AO_5_34 | -2.065 |
| MOM_10 | -0.780 |
| MACD_12_26_9 | -0.936 |
Neurosense Therapeutics Ltd (NRSN) Relative Strength Index (RSI_14) is 27.919, creating a Buy signal.
Neurosense Therapeutics Ltd (NRSN) Stochastic %K is 22.046, creating a Neutral signal.
Neurosense Therapeutics Ltd (NRSN) Stochastic %D is 15.771, creating a Buy signal.
Neurosense Therapeutics Ltd (NRSN) CCI_20 is -104.542, creating a Buy signal.
Neurosense Therapeutics Ltd (NRSN) Awesome Oscillator (AO) is -2.065, creating a Sell signal.
Neurosense Therapeutics Ltd (NRSN) Momentum (MOM) is -0.780, creating a Sell signal.
Neurosense Therapeutics Ltd (NRSN) Moving Average Convergence Divergence (MACD) is -0.936, creating a Sell signal.
Neurosense Therapeutics Ltd (NRSN) Moving Average
2026-11-07
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 1.441 | Buy |
| MA_10 | 1.838 | Sell |
| MA_20 | 2.358 | Sell |
| MA_60 | 5.323 | Sell |
| MA_200 | 12.417 | Sell |
| MA_250 | 13.803 | Sell |
Neurosense Therapeutics Ltd (NRSN) 5-Day simple moving average is 1.441, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Buy.
Neurosense Therapeutics Ltd (NRSN) 10-Day simple moving average is 1.838, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Sell.
Neurosense Therapeutics Ltd (NRSN) 20-Day simple moving average is 2.358, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Sell.
Neurosense Therapeutics Ltd (NRSN) 60-Day simple moving average is 5.323, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Sell.
Neurosense Therapeutics Ltd (NRSN) 200-Day simple moving average is 12.417, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Sell.
Neurosense Therapeutics Ltd (NRSN) 250-Day simple moving average is 13.803, while Neurosense Therapeutics Ltd (NRSN) share price is $, making it a Sell.
Related articles
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.